Company-wide revenue
Reported revenue in 2020 ¥46.75B Reported revenue in 2024 ¥65.26B
- growth amount
- +¥18.51B
- growth annualized
- +8.7%
- growth total
- +39.6%
Japanese company profile · 2929
Pharma Foods International Co., Ltd.
In its FY2024 public filing, Pharma Foods International Co., Ltd. reports B2B business, BtoC business, Biomedical business. The page shows business-level revenue and profit where the source disclosures support comparison.
Original Japanese company name: 株式会社ファーマフーズ
English company name recorded in Japan's EDINET filer data. English company name source
Reported company-wide figures
What does this company do?
What does this company do?
Pharma Foods International Co., Ltd.'s largest reported business by revenue in FY2024 was BtoC business.
The business with the highest reported segment profit in FY2024 was BtoC business.
FY2024 · fiscal year ended July 2025 View original filing ↗ The source document may be in Japanese.
Business structure
How does it make money?
| Business | Sales | Revenue share | Operating profit |
|---|---|---|---|
| BtoC business | ¥56.73B ↗ | 86.9% | ¥3.7B ↗ |
| B2B business | ¥8.18B ↗ | 12.5% | ¥1.25B ↗ |
| Biomedical business | ¥331M ↗ | 0.5% | −¥378M ↗ |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2024 · fiscal year ended July 2025. Revenue and profit are shown only where the filing and data support a comparison.
Original Japanese label
- B2B business
- BtoB事業
- BtoC business
- BtoC事業
- Biomedical business
- バイオメディカル事業
- Business label unavailable in English
- ＢtoＢ事業
- Business label unavailable in English
- ＢtoＣ事業
- Sales
- 売上高
- Operating profit
- 営業利益
Original Japanese label
- B2B business
- BtoB事業
- BtoC business
- BtoC事業
- Biomedical business
- バイオメディカル事業
- Business label unavailable in English
- ＢtoＢ事業
- Business label unavailable in English
- ＢtoＣ事業
- Sales
- 売上高
- Operating profit
- 営業利益
What is growing?
What is growing?
Business revenue growth
Biomedical business
Reported revenue in 2020 ¥375M Reported revenue in 2024 ¥331M
- growth amount
- −¥44M
- growth annualized
- -3.1%
- growth total
- -11.7%
View original filing
This describes a reported period; it is not a forecast.
What has changed?
What has changed?
Not disclosed or not safely comparable in the available filings.
Source
Public filing
FY2024 · fiscal year ended July 2025
The source document may be in Japanese.
Filing ID: S100WW38
View original filing ↗Ask about this company
Ask about this company
The source document may be in Japanese.